# Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma

> **NCT03108027** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 38 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
- **DRUG:** Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
- **DRUG:** Treatment C: Placebo (morning dose) and placebo (evening dose)

## Key facts

- **NCT ID:** NCT03108027
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-26
- **Primary completion:** 2018-02-24
- **Final completion:** 2018-02-24
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03108027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03108027, "Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03108027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*